German Austerity Measures Continue As Firms Dispute How Much Has Already Been Saved
This article was originally published in The Pink Sheet Daily
Despite overall economic growth, the German health ministry refuses to lift the pharmaceutical price freeze or obligatory rebate to health insurers, saying industry is coping well with them; firms say they have already sacrificed more than had initially been asked.
You may also be interested in...
German elections have led to the possibility of several coalition government constellations, but none are particularly good for the pharmaceutical industry.
European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation
German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.
The German pharmaceutical market has dealt impressively with the government’s cost-cutting measures, but they are beginning to take their toll on R&D and innovation, industry maintains.